澳华内镜(688212) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥123,727,829.72, a decrease of 26.92% compared to ¥169,298,973.87 in the same period last year[3] - The net profit attributable to shareholders was -¥28,791,459.68, representing a decline of 1,143.36% from a profit of ¥2,759,505.20 in the previous year[3] - The basic and diluted earnings per share were both -¥0.21, down 1,150.00% from ¥0.02 in the same period last year[3] - Net profit for Q1 2025 was a loss of ¥28,805,606.78, compared to a profit of ¥2,553,872.74 in Q1 2024, indicating a significant decline in profitability[17] - The company reported a basic and diluted earnings per share of -¥0.21 for Q1 2025, compared to ¥0.02 in Q1 2024[18] - The company experienced a significant decline in net profit due to market adjustments and lower sales performance[6] Cash Flow and Liquidity - The net cash flow from operating activities was -¥79,479,605.75, an improvement from -¥104,090,525.46 in the previous year[3] - Cash received from sales of goods and services in Q1 2025 was ¥149,454,697.92, an increase of 15% from ¥130,194,843.84 in Q1 2024[20] - The total cash and cash equivalents at the end of the period were CNY 181,032,041.34, down from CNY 250,197,696.22 at the beginning of the period[22] - Cash flow from operating activities for Q1 2025 was -83,949,334.17 RMB, compared to -80,539,195.67 RMB in Q1 2024[29] - The total cash and cash equivalents at the end of Q1 2025 was 143,051,373.39 RMB, an increase from 87,078,987.30 RMB at the end of Q1 2024[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,722,612,149.61, a decrease of 1.49% from ¥1,748,676,638.82 at the end of the previous year[4] - The company's current assets totaled ¥957,750,695.27, down from ¥992,858,871.93, indicating a decrease of about 3.54%[12] - The total liabilities increased to ¥392,706,734.17 in the latest reporting period from ¥368,197,409.69 in the previous period, marking an increase of approximately 7%[14] - The total equity attributable to shareholders decreased to ¥1,315,496,010.83 from ¥1,366,055,677.44, reflecting a decline of about 4%[14] - The company's total assets decreased to CNY 1,694,423,869.91 from CNY 1,710,087,323.98[25] Research and Development - Research and development expenses totaled ¥41,759,818.78, accounting for 33.75% of operating revenue, an increase of 7.48 percentage points from 26.27%[4] - Research and development expenses for Q1 2025 were ¥41,759,818.78, slightly down from ¥44,482,962.56 in Q1 2024, showing a decrease of about 6%[17] - Research and development expenses for Q1 2025 were CNY 38,845,966.70, slightly lower than CNY 39,018,418.14 in Q1 2024[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,022[8] - The company reported no significant changes in shareholder relationships or actions during the reporting period[10] Other Financial Metrics - Non-recurring gains and losses amounted to ¥2,209,597.44 after tax, with government subsidies contributing ¥2,419,693.28[5][6] - The company recorded a tax expense of -¥8,879,820.56 in Q1 2025, compared to -¥2,869,603.72 in Q1 2024, indicating a higher tax impact on the loss[17] - Other comprehensive income after tax for Q1 2025 was ¥1,956,247.66, contrasting with -¥1,299,385.97 in Q1 2024, showing a recovery in this area[18] - The company reported a credit impairment loss of -3,935,448.76 RMB in Q1 2025, compared to -3,321,455.23 RMB in Q1 2024[28] - The company’s investment income for Q1 2025 was -190,749.55 RMB, a decrease from 1,238,833.69 RMB in Q1 2024[28]